Stock Financial Ratios, Dividends, Split History

KAMN / Kaman Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price72.17
Volume150,500.00
Market Cap ($M)1,758.51
Enterprise Value ($M)1,735.92
Book Value ($M)642.33
Book Value / Share23.01
Price / Book2.78
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 27,611,000
Weighted Average Number Of Diluted Shares Outstanding 28,418,000
Common Shares Outstanding 27,801,851
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.05
Return on Assets (ROA)0.03
Return on Equity (ROE)0.09
Balance Sheet (mrq) ($M)
Assets1,485.76
Liabilities843.43
Quick Ratio1.87
Current Ratio3.06
Income Statement (mra) ($M)
Fair Value Inputs Long Term Revenue Growth Rate0.01
Sales Revenue Net1,805,909,000.00
Operating Income114.17
Net Income49.83
Earnings Per Share Basic1.80
Earnings Per Share Diluted1.75
Cash Flow Statement (mra) ($M)
Cash From Operations79.89
Cash from Investing-31.84
Cash from Financing-31.84
Identifiers and Descriptors
CUSIP483548103
Central Index Key (CIK)54381
Related CUSIPS
483548953 483548903

Split History

Stock splits are used by Kaman Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Ingersoll (IR) Hikes Dividend by 18% to Reward Shareholders

2018-06-12 zacks
Ingersoll-Rand Plc (IR - Free Report) recently raised its quarterly dividend by 18% year over year to 53 cents per share or $2.12 on an annualized basis. The increased sum will be paid on Sep 28 to shareholders on record as of Sep 7. The industrial goods manufacturer has been paying uninterrupted quarterly cash dividends since 1919 and annual dividends since 1910. A steady payout is part of the long-term strategy of Ingersoll to provide attractive risk-adjusted returns to its stockholders. (6-0)

Kaman Wins $69M USAF JPF Order, Opens New Store in Illinois

2018-06-05 zacks
Kaman Corporation (KAMN - Free Report) recently announced that its Aerospace segment has secured its foremost order under Option 14 of its present U.S. Air Force (USAF) Joint Programmable Fuze (JPF) contract. The estimated worth of this deal is $69 million. Kaman has been providing JPF’s to USAF since 2002. The JPF permits the setting of a weapon to be automated in the flight wing and is presently USAF’s preferred bomb fuze. (15-0)

The Zacks Analyst Blog Highlights: Caterpillar, Regal Beloit, Zebra Technologies, Kaman and EnerSys

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , Regal Beloit Corporation (RBC - Free Report) , Zebra Technologies Corporation (ZBRA - Free Report) , Kaman Corporation (KAMN - Free Report) and EnerSys (ENS - Free Report) . (99-0)

5 Manufacturing Stocks to Grab After Blockbuster Jobs Report

2018-06-04 investorplace
Fresh milestones in Friday’s Labor Department jobs’ report hinted at a bustling American economy. The S&P 500 index rose more than 1% in the weekend trading session, as the news of 223,000 job creations in the United States mirrored healthy gains across a wide range of industries, from transportation and manufacturing, to retailing and healthcare. (52-0)

5 Manufacturing Stocks to Grab on Blockbuster Jobs Report

2018-06-04 zacks
Fresh milestones in Friday’s Labor Department jobs’ report hinted at a bustling American economy. The S&P 500 index rose more than 1% in the weekend trading session, as the news of 223,000 job creations in the United States mirrored healthy gains across a wide range of industries, from transportation and manufacturing, to retailing and healthcare. Among all, the manufacturing sector calls for much needed attention. (51-0)

CUSIP: 483548103